Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Eli Lilly phase 3 trials reveal once-weekly insulin efsitora as a non-inferior alternative to daily basal insulins for type 2 d...
Efsitora met the primary endpoint in both QWINT-2 and QWINT-4 with once-a-week dosing regimen for people living with type 2 d...
Novo Nordisk confirms there is no anticipated shortage of Wegovy in Denmark, despite prior warnings from the Danish Medicines A...
Eli Lilly has settled with Totality Medispa over counterfeit Mounjaro and Zepbound sales. The spa will pay damages and cease us...
https://www.wsj.com/livecoverage/stock-market-today-dow-jones-05-14-2024/card/lilly-settles-with-spa-selling-mounjaro-zepbound-...
Argus Research analyst David Toung maintains Eli Lilly and Co (NYSE:LLY) with a Buy and raises the price target from $770 to...
